<DOC>
	<DOCNO>NCT02342704</DOCNO>
	<brief_summary>The primary objective study assess effect natalizumab compare fingolimod evolution new on-treatment T1-gadolinium-enhancing ( Gd+ ) lesions persistent black hole ( PBH ) 52 week . The secondary objective study study population ass effect natalizumab compare fingolimod : magnetic resonance imaging ( MRI ) measure central nervous system ( CNS ) tissue destruction measure number new T1-Gd+ lesion ; various MRI measure disease activity ; No Evidence Disease Activity ( NEDA ) ; Relapse treatment 52 week ; The change information process speed measure Symbol Digit Modalities Test ( SDMT ) .</brief_summary>
	<brief_title>Impact Natalizumab Versus Fingolimod Relapsing-Remitting Multiple Sclerosis ( RRMS ) Participants</brief_title>
	<detailed_description>This study also include Diffusion Tensor Imaging ( DTI ) sub-study include healthy volunteer . Healthy volunteer receive study medication .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Key Inclusion Criteria MS Patients : Must document diagnosis relapse MS ( McDonald 2010 Criteria ) study screen EDSS score 0.0 5.5 . If subject Betaseron , Rebif , Avonex , Copaxone , Extavia , Tecfidera , Aubagio ( BRACETA ) study screening : He/she must therapy least 6 month ( unless experience highly active disease ) , least 9 T2hyperintense lesion brain MRI scan , experience ≥1 relapse within last 6 month prior study screen ≥1 new T1Gd+ lesion brain MRI scan perform ≤6 month prior study screen ≥2 new T2 lesion brain MRI scan perform ≤6 month prior study screen , comparison make T2 MRI scan perform 18 month study screen If subject highly active disease , regardless whether diseasemodifying therapy ( DMT ) naïve previous exposure Betaseron , Rebif , Avonex , Copaxone , Extavia , Tecfidera , Aubagio ( BRACE ) TA ) , must ≥2 disable relapse 12 month prior study screen either ≥1 new T1Gd+ lesion brain MRI scan perform ≤6 month prior study screen ≥2 new T2 lesion brain MRI scan perform ≤6 month prior study screen , comparison make T2 MRI scan perform 18 month study screen Key Exclusion Criteria MS Patients : Diagnosis Primary Progressive Multiple Sclerosis and/or Secondary Progressive Multiple Sclerosis . History positive test result study screen human immunodeficiency virus ( HIV ) , hepatitis C virus ( HCV ) antibody current hepatitis B infection ( define positive hepatitis B surface antigen [ HBsAg ] and/or hepatitis B core antibody [ HBcAb ] ) . Prior treatment natalizumab fingolimod . History know active malignant disease , include solid tumor hematologic malignancy ( subject cutaneous basal squamous cell carcinoma completely excise consider cured prior study screen remain eligible ) . History opportunistic infection clinically significant major disease , determine Investigator . A clinically significant infectious illness ( e.g. , pneumonia , septicemia ) within 1 month prior study screen . History drug alcohol abuse ( define Investigator ) within 1 year prior study screening . Prior history immunosuppressant use ( e.g. , mitoxantrone , azathioprine , methotrexate , cyclophosphamide , mycophenolate , cladribine , rituximab ) , exposure intravenous immunoglobulin ( IGIV ) , monoclonal antibody , cytokine , growth factor , soluble receptor , recombinant product , fusion protein last 12 month prior study screen . History myocardial infarction , unstable angina , stroke , transient ischemic attack , decompensated heart failure last 6 month . Treatment Class Ia ( e.g. , procainamide , quinidine , ajmaline , disopyramide ) Class III ( amiodarone , bretylium , dofelitide , sotalol , ibulitide , azilimide ) antiarrhythmic drug . Concurrent therapy drug slow heart rate ( e.g. , betablockers , heartrate lower calcium channel blocker diltiazem verapamil , digoxin ) . Hypertension control prescribed medication . History severe respiratory disease , pulmonary fibrosis class III IV chronic obstructive pulmonary disease . The use live live attenuate vaccination within 8 week study screen . Key Inclusion Criteria Healthy Volunteers : Subjects generally healthy demonstrate physical examination medical history , history evidence major illness , disease , disorder . Subjects childbearing potential must practice effective contraception willing able continue contraception duration study . History drug alcohol abuse ( define Investigator ) within 1 year prior study screen . Key Exclusion Criteria Healthy Volunteers : Claustrophobia sufficient interfere generate reliable MRI scan . History major illness include neurological disorder determine Investigator . Presence metal device affect MRI ( e.g. , type electronic , mechanical magnetic implant , cardiac pacemaker , aneurysm clip , implanted cardiac defibrillator ) potential ferromagnetic foreign body ( metal sliver , metal shaving , metal object ) , would contraindication MRI . Women currently pregnant breastfeeding , positive pregnancy test result screen . NOTE : Other protocol define Inclusion/Exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>